Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambalal Sarabhai Enterprises Ltd stock PB Ratio (=2.26) is close to 1-year high of 2.26.
The historical rank and industry rank for Ambalalrabhai Enterprises's PB Ratio or its related term are showing as below:
NSE:AMBALALSA'
s PB Ratio Range Over the Past 10 Years
Min: 1.2 Med: 2.49 Max: 6.49
Current: 2.22
During the past 13 years, Ambalalrabhai Enterprises's highest PB Ratio was 6.49. The lowest was 1.20. And the median was 2.49.
NSE:AMBALALSA's PB Ratio is ranked worse than 55.98% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs NSE:AMBALALSA: 2.22
During the past 12 months, Ambalalrabhai Enterprises's average Book Value Per Share Growth Rate was 13.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 22.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ambalalrabhai Enterprises was 57.60% per year. The lowest was -11.60% per year. And the median was 22.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Ambalalrabhai Enterprises PB Ratio Related Terms
Ambalalrabhai Enterprises PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ambalalrabhai Enterprises's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambalalrabhai Enterprises PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ambalalrabhai Enterprises's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ambalalrabhai Enterprises's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Ambalalrabhai Enterprises (NSE:AMBALALSA) has a PB Ratio of 2.22 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ambalalrabhai Enterprises and its competitors. This is 11% below median its historical median of 2.49. Over the past decade, Ambalalrabhai Enterprises' PB Ratio has ranged from 1.20 to 6.49. According to the industry distribution chart, Ambalalrabhai Enterprises ranks #515 out of 920 companies in the Drug Manufacturers industry, placing it in the top 56%.
Is Ambalalrabhai Enterprises' PB Ratio too high?
Ambalalrabhai Enterprises' current PB Ratio of 2.22 is 11% below median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 6.49. The Drug Manufacturers industry median PB Ratio is 1.98. Ambalalrabhai Enterprises' value of 2.22 is 12.1% above this industry median. Based on the distribution chart, Ambalalrabhai Enterprises ranks #515 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ambalalrabhai Enterprises has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ambalalrabhai Enterprises' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ambalalrabhai Enterprises ranks #515 out of 920 companies for PB Ratio. This places Ambalalrabhai Enterprises in the lower half of its industry. The industry median PB Ratio is 1.98. Ambalalrabhai Enterprises' value of 2.22 is 12.1% above this benchmark. Historically, Ambalalrabhai Enterprises' own PB Ratio has ranged from 1.20 to 6.49 over the past decade. While the company's 10-year median is 2.49 vs. the industry median of 1.98, Ambalalrabhai Enterprises has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambalalrabhai Enterprises's current PB Ratio of 2.22 is 12.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Ambalalrabhai Enterprises and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambalalrabhai Enterprises's current PB Ratio is 2.22, which is 11% below median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambalalrabhai Enterprises stock overvalued right now?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises (NSE:AMBALALSA) is currently considered Fairly Valued. The stock's GF Value™ is ₹41.96, compared to a current price of ₹45.94 — trading 9.5% above its estimated fair value. The current PB Ratio is 2.22, which is 11% below median its 10-year median of 2.49 and 12.1% above the Drug Manufacturers industry median of 1.98. Ambalalrabhai Enterprises' overall GF Score™ is 52/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Ambalalrabhai Enterprises (NSE:AMBALALSA), the current PB Ratio is 2.22 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambalalrabhai Enterprises (NSE:AMBALALSA) Overvalued in 2026?
Based on GuruFocus' analysis, Ambalalrabhai Enterprises stock appears to be overvalued.
The current stock price of ₹45.94 is trading 9.5% above its estimated GF Value™ of ₹41.96.
GuruFocus considers Ambalalrabhai Enterprises to be Fairly Valued.
Key valuation signals for NSE:AMBALALSA:
PB Ratio: 2.22 (11% below median its 10-year median of 2.49)
GF Value™: ₹41.96 vs. price of ₹45.94 (9.5% above fair value)
Industry Position: 12.1% above the Drug Manufacturers median (#515 of 920)
No single metric tells the full story. See the NSE:AMBALALSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambalal Sarabhai Enterprises Ltd is an India-based company engaged in the manufacturing and marketing of Drugs and Formulation. The operating segment of the company is Pharmaceutical Products. It serves domestic as well as International markets.
52GF Score
Get the complete analysis for NSE:AMBALALSA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMBALALSA has been successfully added to your 
